Readystate Asset Management LP Purchases New Stake in 2seventy bio, Inc. (NASDAQ:TSVT)

Readystate Asset Management LP purchased a new stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,161 shares of the company’s stock, valued at approximately $53,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Venator Management LLC raised its position in shares of 2seventy bio by 49.2% during the 2nd quarter. Venator Management LLC now owns 485,000 shares of the company’s stock valued at $1,867,000 after acquiring an additional 160,000 shares in the last quarter. BBR Partners LLC raised its position in shares of 2seventy bio by 620.0% during the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after acquiring an additional 155,000 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of 2seventy bio during the 3rd quarter valued at approximately $64,000. Nisa Investment Advisors LLC acquired a new stake in shares of 2seventy bio during the 2nd quarter valued at approximately $52,000. Finally, Marshall Wace LLP raised its position in shares of 2seventy bio by 50.4% during the 2nd quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock valued at $2,568,000 after acquiring an additional 223,408 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

2seventy bio Trading Down 6.6 %

TSVT stock opened at $3.41 on Friday. 2seventy bio, Inc. has a 12-month low of $2.15 and a 12-month high of $6.40. The stock’s 50 day simple moving average is $4.42 and its 200 day simple moving average is $4.39. The firm has a market cap of $175.92 million, a P/E ratio of -1.83 and a beta of 1.69.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.